The estimated Net Worth of Corrine Savill is at least $5.03 Million dollars as of 1 February 2024. Corrine Savill owns over 40,000 units of Cullinan Oncology stock worth over $3,703,700 and over the last 3 years Corrine sold CGEM stock worth over $1,329,200.
Corrine has made over 5 trades of the Cullinan Oncology stock since 2022, according to the Form 4 filled with the SEC. Most recently Corrine exercised 40,000 units of CGEM stock worth $172,000 on 1 February 2024.
The largest trade Corrine's ever made was exercising 40,000 units of Cullinan Oncology stock on 1 February 2024 worth over $172,000. On average, Corrine trades about 22,500 units every 71 days since 2022. As of 1 February 2024 Corrine still owns at least 205,990 units of Cullinan Oncology stock.
You can see the complete history of Corrine Savill stock trades at the bottom of the page.
Corrine's mailing address filed with the SEC is C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142.
Over the last 4 years, insiders at Cullinan Oncology have traded over $29,405,190 worth of Cullinan Oncology stock and bought 2,950,136 units worth $38,299,215 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Ansbert Gadicke, and Morana Jovan Embiricos. On average, Cullinan Oncology executives and independent directors trade stock every 14 days with the average trade being worth of $914,589. The most recent stock trade was executed by Jennifer Michaelson on 5 September 2024, trading 8,000 units of CGEM stock currently worth $144,720.
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Cullinan Oncology executives and other stock owners filed with the SEC include: